- In patients with high-grade colorectal neuroendocrine carcinoma (HGNEC), chemotherapy combined with resection of the primary tumor led to better survival than chemotherapy alone.
Why this matters
- HGNECs are rare, but on the rise, and the optimal treatment strategy is unknown.
- Analysis of 1208 patients with HGNEC (50% women; median age, 65 years), drawn from the National Cancer Database: 37.4% had primary tumors of the rectum, 62.5% had primary tumors of the colon.
- Funding: None.
- 61.3% of patients underwent surgery of the primary tumor, 64.4% underwent chemotherapy, and 21.2% underwent radiation therapy.
- Factors associated with improved survival included surgical resection (HR, 0.54; P<.001 chemotherapy p and primary tumor in the rectum>
- There was no significant association between radiation therapy and overall survival.
- When the analysis was limited to patients with metastatic disease, there was a still a significant association between survival and surgical resection (HR, 0.51; P<.001 and chemotherapy p>
- Retrospective analysis.
- Records did not include extent of metastatic disease, which can affect treatment choice.